All three projects rely on genetically modified mice and the production of purified proteins and polyclonal and monoclonal antibodies. Accordingly, all three projects will be supported by the Mouse Model and Protein Expression Core (Core A), led by Dr. Loren Fong. Dr. Fong is an expert in a wide variety of practical techniques in cellular and molecular biology, including growing and manipulating mouse embryonic stem cells and the use of mouse models in biomedical research. This expertise has paid huge dividends for this PPG. Dr. Fong, working with Drs. Reue, Young, and Tontonoz, has generated conventional and tissue- specific Lipin2, Lipin3, Idol, and Tle3 knockout mice. In addition, the Core houses and genotypes mice, backcrosses mice onto inbred strains, maintains animal protocols, and organizes histological studies on mouse models. The Core also produces purified proteins for biochemical studies and for generating polyclonal and monoclonal antibodies;this has been an essential function, since our PPG has focused on newly discovered molecules, for which few reagents exist. During the prior funding period, Drs. Bensadoun, Fong and Young produced multiple antibody reagents for this PPG. Their expertise and experience will be a boon for the new antibody projects proposed in this application. Aside from antibody reagents, the Core will also produce purified recombinant proteins for biochemical and structural biology studies. All three projects of the PPG will use Core A.
This Program Project Grant proposes to define the molecular mechanisms that regulate lipid metabolism and adiposity-two events that play centrol roles in the pathogenesis of metablic disesase (e.g., obeisity and atherosclerosis). The Mouse Model and Protein Expression Core will support the PPG's goals by providing new mouse models, antibodies, and recombinant proteins to all three projects.
|Beigneux, Anne P; Fong, Loren G; Bensadoun, André et al. (2015) GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and thereby prevent lipoprotein lipase binding. Circ Res 116:624-32|
|Bensadoun, André; Mottler, Charlene D; Pelletier, Chris et al. (2014) A new monoclonal antibody, 4-1a, that binds to the amino terminus of human lipoprotein lipase. Biochim Biophys Acta 1841:970-6|
|Csaki, Lauren S; Dwyer, Jennifer R; Li, Xia et al. (2014) Lipin-1 and lipin-3 together determine adiposity in vivo. Mol Metab 3:145-54|
|Turlo, Kirsten; Leung, Calvin S; Seo, Jane J et al. (2014) Equivalent binding of wild-type lipoprotein lipase (LPL) and S447X-LPL to GPIHBP1, the endothelial cell LPL transporter. Biochim Biophys Acta 1841:963-9|
|Goulbourne, Chris N; Gin, Peter; Tatar, Angelica et al. (2014) The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries. Cell Metab 19:849-60|
|Sha, Haibo; Sun, Shengyi; Francisco, Adam B et al. (2014) The ER-associated degradation adaptor protein Sel1L regulates LPL secretion and lipid metabolism. Cell Metab 20:458-70|
|Zhang, Peixiang; Verity, M Anthony; Reue, Karen (2014) Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle. Cell Metab 20:267-79|
|Adeyo, Oludotun; Allan, Bernard B; Barnes 2nd, Richard H et al. (2014) Palmoplantar keratoderma along with neuromuscular and metabolic phenotypes in Slurp1-deficient mice. J Invest Dermatol 134:1589-98|
|Plengpanich, Wanee; Young, Stephen G; Khovidhunkit, Weerapan et al. (2014) Multimerization of glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) and familial chylomicronemia from a serine-to-cysteine substitution in GPIHBP1 Ly6 domain. J Biol Chem 289:19491-9|
|Jiang, Haibo; Goulbourne, Chris N; Tatar, Angelica et al. (2014) High-resolution imaging of dietary lipids in cells and tissues by NanoSIMS analysis. J Lipid Res 55:2156-66|
Showing the most recent 10 out of 62 publications